Pulmonary hypertension is associated with pulmonary vascular remodelling, rendering the vessels unresponsive to vasodilators. An understanding of the mechanisms which cause this remodelling is required, which is likely to be linked to changes in vascular tone whether stimulated by hypoxia or other factors. One way to approach this is to try to understand the intracellular signalling pathways associated with hypoxia in pulmonary artery cells. This understanding could provide opportunities for therapeutic intervention using agents which will interfere with the signalling systems. (Thorax 1996;51:864-866) 
Pulmonary hypertension may occur as a primary disease (primary pulmonary hypertension, PPH) or as a serious and common sequel to most types of cardiopulmonary disease In both proximal and peripheral remodelling local growth factors are likely to be important. We believe that these growth factors have two main characteristics: firstly, that they are also vasoconstrictors -that is, there is a link between cell replication and vascular control ("cell growth-vasomotor coupling") -and, secondly, that they are derived from the endothelial cell which probably receives the primary stimulus, whether it be stretch, sheer force, or hypoxia. The most likely contenders at present include endothelin-1 (ET-1) and platelet-derived growth factor (PDGF). These are probably opposed by the physiological dilators nitric oxide and atrial natriuretic peptide.
Whatever growth promoting factor is postulated, there is likely to be a common mechanism that transduces a stimulus such as hypoxia or stretch into a response such as vascular cell replication. We need to understand this mechanism. The flourishing discipline of cell signalling is likely to provide the key (fig 1) . In addition, a greater understanding of these intracellular signalling mechanisms may identify possible target sites for the development of novel treatments for pulmonary hypertension. Figure 2 Potential pathways for receptor-mediated second messenger generation and downstream effects leading to DNA synthesis and cell division. Growth factors such as PDGF bind to specific receptors on the cell membrane resulting in association ofPLCy to the activated receptor and subsequent hydrolysis ofPtdInsP2 to form InsP3 and DAG. InsP3 binds to specific receptors on endoplasmic reticulum which results in the release of calcium, necessary for cell contraction. DAG activates PKC whose activity is also regulated by calcium levels. Mitogens such as ET-1 can also activate this pathway, however, this receptor activates Activation of M\AP kinases occurs in response to many agonists such as PDGF and ET-1 in a number of different cell types and has been shown to lie downstream from PKC. MAP kinases and other signalling pathways may provide further links in the chain of signalling events leading to cell division. The realisation that various kinases may be important in cell signalling has led to the further identification of specific phosphatases which can inhibit these processes.'" Future research will concentrate on this balance between phosphatases and kinases.
Scientific background
Therapeutic potential Different growth factors activate different signalling events within the cell. Great progress has been made in the understanding of these pathways and it is reasonable to expect that activation of a particular pathway occurs when a vascular cell is stimulated to contract or divide. If we can map this pathway in a particular vascular cell in response to a particular stimulus such as hypoxia, then intervention could prevent the unwanted response. Clearly, this form of intervention at an intracellular level is novel but potentially very exciting -whether in vascular cells of patients with pulmonary hypertension or airway cells of patients with asthma.
Conclusion
Pulmonary hypertension and pulmonary vascular remodelling are linked and mutually self-sustaining. The key to this link is likely to be found in the processes of cell signalling which occur within pulmonary vascular cells in response to stimuli such as hypoxia. Interruption of the link and prevention of the vicious circle of "cell growth-vasomotor coupling" may be the basis of future therapy.
